Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep advocating for trials in all populations! #ACR25 @RheumNow Abstr#0720 https://t.co/gDj5IQMJOc

• https://x.com/EBRheum/status/1982485372568482227/photo/1

#ACR25 Abstr#776 2-Year SELECT-GCA RCT showed that #GCA patients receiving continuous UPA15 to 2-yr maintained their remission (69%) vs those who switched to PBO after in remission for ≥24 weeks (29%). Lower serious infection but higher herpes zoster in UPA15. One VTE @RheumNow https://t.co/FCTNqCVxiZ

• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1
• https://x.com/Yuz6Yusof/status/1982486937022939200/photo/1

Fascinating: tDR-1, a microbial sRNA, appears protective for RA in at risk ACPA+ pts: - tDR-1 higher = less develop RA - can predict seropos RA development - in vitro type 1 IFN mapping checks out Useful in itself, but importantly: why does it happen? #ACR25 ABST0775 @RheumNow https://t.co/ep99dNAzFV

• https://x.com/drdavidliew/status/1982487047119233037/photo/1
• https://x.com/drdavidliew/status/1982487047119233037/photo/1
• https://x.com/drdavidliew/status/1982487047119233037/photo/1
• https://x.com/drdavidliew/status/1982487047119233037/photo/1

No seasonal pattern in GCA! We have also looked at this in our data and similarly found no trends It sure feels like GCA comes in waves, but data does not bear this out #ACR25 @RheumNow Abstr#0754 https://t.co/4y2elYmCRT

• https://x.com/EBRheum/status/1982487133937193089/photo/1

Lindberg et al. Nationwide case-control study in Sweden. Big increase in risk of DVT/PE in AAV, most marked early after diagnosis @RheumNow #ACR25 Abstr#718 https://t.co/FpDcbX15hm

• https://x.com/RichardPAConway/status/1982483107790872801/photo/1

Novelli et al. Upadacitinib in male vs female PsA. Data from SELECT-PsA studies. Appears equivalent in males and females, contrasting with TNFi/IL17i data. @RheumNow #ACR25 Abstr#557 https://t.co/fMKsbCkju0

• https://x.com/RichardPAConway/status/1982482604373787008/photo/1

In a novel Geri-Rheum clinic, cognitive screening revealed 35% impairment among adults >55 yrs. Common deficits: visuospatial, attention & recall. Early geriatric screening = earlier intervention. A model for age-friendly rheum care in action. @RheumNow #ACR25 Abstract #0226 https://t.co/lIAcrZvL4H

• https://x.com/JihaRheum/status/1982482353097224699/photo/1

Heydari-Kamjani et al. Risk of DILI with avacopan. Real world study, propensity score matching. Risk DILI 2% with avacopan vs 1.9% PBO @RheumNow #ACR25 Abstr#724 https://t.co/UhVkcXEYjF

• https://x.com/RichardPAConway/status/1982482352962998313/photo/1

Ogdie et al. Week 24 results of SOLSTICE study. Guselkumab in TNF-IR in PsA. Good efficacy on skin and joint disease. No difference seen in Q4 vs Q8 weekly doses. @RheumNow #ACR25 Abstr#563 https://t.co/ztK0O9iKb8

• https://x.com/RichardPAConway/status/1982481346682396779/photo/1

Observational study of fibrinogen for diagnosis of GCA At a cutoff of 4.7, roughly similar diagnostic performance as compared to ESR/CRP Kind of neat, but does not appear to have additive benefit #ACR25 @RheumNow Abstr#0750 https://t.co/xy2qn4jHXP

• https://x.com/EBRheum/status/1982481345915040253/photo/1

ILD found in 30% of Sjögren’s pts w/ HRCT. A new nomogram-based tool (AUC 0.8) predicts ILD risk using age, ESR, C3, hypergammaglobulinemia & anti-La/SSB. Goal: guide HRCT referrals & catch ILD earlier. @RheumNow #ACR25 Abstract #0510 https://t.co/FvAprq8eol

• https://x.com/JihaRheum/status/1982478326150447224/photo/1

2-Year data from SELECT-GCA Phase 3 UPA in GCA Re-randomization & 52 weeks extension UPA 15mg vs. PBO -Risk of flare 90% lower -Complete remission 70% vs 20% -Cumulative GC 1g difference -No new safety signal The quick relapse after stopping UPA indicates we are really looking https://t.co/c1khywnPNv

• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1
• https://x.com/AurelieRheumo/status/1982478272697909405/photo/1

Immune-Mediated Necrotizing Myopathy @EleniTiniakou #ACR25 *Younger pts tend to have a more aggressive disease *IVIG and RTX can be considered first-line rx for anti-HMGCR and anti-SRP+, respectively *CYC and plasmapheresis may be options in cases of aggressive disease https://t.co/zWDX79gqlf

• https://x.com/RheumQuarterly/status/1982461272500097265/photo/1

Abstract 0806 Compared to belimumab, Anifrolumab associated with: ↑ infection risk b (HR 1.40, 95% CI 1.05–1.88) ↑ herpes zoster (HR 3.94) & COVID-19 (HR 1.66) No diff in mortality or hospital use 📈 3-yr infection: 38.3% vs 21.3% @RheumNow #ACR25